Trial Profile

Guselkumab for hidradenitis suppurativa, a mode of action study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Guselkumab (Primary)
Indications Hidradenitis suppurativa
Focus Pharmacodynamics
Acronyms HiGUS

Most Recent Events

22 Feb 2023 Status changed to completed, as per results published in the British Journal of Dermatology.
22 Feb 2023 Results assessing the safety, tolerability, and efficacy of guselkumab, and in particular, its mode of action, in patients with moderate-to-severe hidradenitis suppurativa patients, published in the British Journal of Dermatology.
05 Aug 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Aug 2019).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com